Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

L Kurch; D Hasenclever; R Kluge; T Georgi; L Tchavdarova; M Golombeck; O Sabri; A Eggert; W Brenner; KW Sykora; FM Bengel; C Rossig; D Körholz; M Schäfers; T Feuchtinger; P Bartenstein; RA Ammann; T Krause; Ernst-Christian Urban; Reingard Aigner; S Gattenlöhner; W Klapper; C Mauz-Körholz

doi:10.1002/pbc.27539

Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

L Kurch
, D Hasenclever
, R Kluge
, T Georgi
, L Tchavdarova
, M Golombeck
, O Sabri
, A Eggert
, W Brenner
, KW Sykora
, FM Bengel
, C Rossig
, D Körholz
, M Schäfers
, T Feuchtinger
, P Bartenstein
, RA Ammann
, T Krause
, Ernst-Christian Urban
, Reingard Aigner

S Gattenlöhner, W Klapper, C Mauz-Körholz

Klinische Abteilung für Nuklearmedizin

Publikation: Beitrag in Fachzeitschrift › Originalarbeit

15 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Pediatric Blood and Cancer
DOIs	https://doi.org/10.1002/pbc.27539
Publikationsstatus	Veröffentlicht - 2019

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

301 Medizinisch-theoretische Wissenschaften, Pharmazie
302 Klinische Medizin
305 Andere Humanmedizin, Gesundheitswissenschaften

Forschungsfelder

Krebsforschung

Zugriff auf Dokument

10.1002/pbc.27539

Andere Dateien und Links

Dieses zitieren

Kurch, L., Hasenclever, D., Kluge, R., Georgi, T., Tchavdarova, L., Golombeck, M., Sabri, O., Eggert, A., Brenner, W., Sykora, KW., Bengel, FM., Rossig, C., Körholz, D., Schäfers, M., Feuchtinger, T., Bartenstein, P., Ammann, RA., Krause, T., Urban, E.-C., ... Mauz-Körholz, C. (2019). Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. Pediatric Blood and Cancer. https://doi.org/10.1002/pbc.27539

@article{462ff9e13f1d44dda724bb1ac8a04a4d,

title = "Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.",

author = "L Kurch and D Hasenclever and R Kluge and T Georgi and L Tchavdarova and M Golombeck and O Sabri and A Eggert and W Brenner and KW Sykora and FM Bengel and C Rossig and D K{\"o}rholz and M Sch{\"a}fers and T Feuchtinger and P Bartenstein and RA Ammann and T Krause and Ernst-Christian Urban and Reingard Aigner and S Gattenl{\"o}hner and W Klapper and C Mauz-K{\"o}rholz",

year = "2019",

doi = "10.1002/pbc.27539",

language = "English",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

}

Kurch, L, Hasenclever, D, Kluge, R, Georgi, T, Tchavdarova, L, Golombeck, M, Sabri, O, Eggert, A, Brenner, W, Sykora, KW, Bengel, FM, Rossig, C, Körholz, D, Schäfers, M, Feuchtinger, T, Bartenstein, P, Ammann, RA, Krause, T, Urban, E-C, Aigner, R, Gattenlöhner, S, Klapper, W & Mauz-Körholz, C 2019, 'Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.', Pediatric Blood and Cancer. https://doi.org/10.1002/pbc.27539

TY - JOUR

T1 - Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

AU - Kurch, L

AU - Hasenclever, D

AU - Kluge, R

AU - Georgi, T

AU - Tchavdarova, L

AU - Golombeck, M

AU - Sabri, O

AU - Eggert, A

AU - Brenner, W

AU - Sykora, KW

AU - Bengel, FM

AU - Rossig, C

AU - Körholz, D

AU - Schäfers, M

AU - Feuchtinger, T

AU - Bartenstein, P

AU - Ammann, RA

AU - Krause, T

AU - Urban, Ernst-Christian

AU - Aigner, Reingard

AU - Gattenlöhner, S

AU - Klapper, W

AU - Mauz-Körholz, C

PY - 2019

Y1 - 2019

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000456685600016

UR - https://pubmed.ncbi.nlm.nih.gov/30426671

U2 - 10.1002/pbc.27539

DO - 10.1002/pbc.27539

M3 - Research article

C2 - 30426671

SN - 1545-5009

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

ER -